If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?

TY - JOUR

T1 - If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?

AU - Crotty, Grace F.

AU - Lo, Raymond Y.

AU - Schwarzschild, Michael A.

N1 - Funding Information: G.F.C.: Employment: Massachusetts General Hospital; Fellowship funding: The Edmond J. Safra Fellowship in Movement Disorders.R.Y.L.: Employment: Hualien Tzu Chi Hospital; Grant: “Ministry of Science and Technology (MOST- 107-2511-H-303 -001 -MY2), Taiwan.”M.A.S.: Employment: Massachusetts General Hospital; Consultancies: Eli Lilly & Co. (trial data monitoring committee); Advisory Boards: Denali Therapeutics (clinical advisory board), nQ Medical (clinical advisory board), Chase Therapeutics (clinical advisory board), Cure Parkinson's Trust (Linked Clinical Trial committee), CBD Solutions (scientific advisory board), Parkinson's Foundation (PD GENE steering committee), Michael J. Fox Foundation (scientific advisory board, NILO-PD Steering Committee, PPMI steering committee), World Parkinson Congress (steering committee); Royalties: adenosine A2A knockout mouse license; Grants: NIH 1R13NS111953, NIH U01NS090259, NIH U01NS107009, NIH R01NS110879, R01NS102735 (Chen), Parkinson's Foundation PDF-APT-1407/-1944, Michael J. Fox Foundation biomarkers/DAT imaging/diversity (Jackson)/LRRK2 grants programs, and Farmer Family Foundation Parkinson's Research Initiative; Other: Parkinson Study Group (PSG; chair, Executive Committee), NIH (scientific review committee), and Michael J. Fox Foundation (scientific review committee). Funding Information: G.F.C.: Employment: Massachusetts General Hospital; Fellowship funding: The Edmond J. Safra Fellowship in Movement Disorders.R.Y.L.: Employment: Hualien Tzu Chi Hospital; Grant: “Ministry of Science and Technology (MOST‐ 107‐2511‐H‐303 ‐001 ‐MY2), Taiwan.”M.A.S.: Employment: Massachusetts General Hospital; Consultancies: Eli Lilly & Co. (trial data monitoring committee); Advisory Boards: Denali Therapeutics (clinical advisory board), nQ Medical (clinical advisory board), Chase Therapeutics (clinical advisory board), Cure Parkinson's Trust (Linked Clinical Trial committee), CBD Solutions (scientific advisory board), Parkinson's Foundation (PD GENE steering committee), Michael J. Fox Foundation (scientific advisory board, NILO‐PD Steering Committee, PPMI steering committee), World Parkinson Congress (steering committee); Royalties: adenosine A knockout mouse license; Grants: NIH 1R13NS111953, NIH U01NS090259, NIH U01NS107009, NIH R01NS110879, R01NS102735 (Chen), Parkinson's Foundation PDF‐APT‐1407/‐1944, Michael J. Fox Foundation biomarkers/DAT imaging/diversity (Jackson)/LRRK2 grants programs, and Farmer Family Foundation Parkinson's Research Initiative; Other: Parkinson Study Group (PSG; chair, Executive Committee), NIH (scientific review committee), and Michael J. Fox Foundation (scientific review committee). 2A Funding Information: This research was supported by Farmer Family Foundation Initiative for Parkinson's Disease Research (M.A.S.), a Jane & Alan Batkin Research Fellowship (G.F.C.), The Edmond J. Safra Fellowship in Movement Disorders (G.F.C.), and National Institutes of Health (NIH) grant R01NS110879 (M.A.S.). Funding agencies:

PY - 2020/10/1

Y1 - 2020/10/1

UR - https://www.scopus.com/pages/publications/85092646816

U2 - 10.1002/mds.28240

DO - 10.1002/mds.28240

M3 - 社论

C2 - 33068466

AN - SCOPUS:85092646816

SN - 0885-3185

VL - 35

SP - 1727

EP - 1730

JO - Movement Disorders

JF - Movement Disorders

IS - 10

ER -